289 Tomkiewicz-Pajak L, Hoffman P, Trojnarska O, et al Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure J Thorac Cardiovasc Surg 2014;147(4):1284–1290 290 Egbe AC, Connolly HM, Niaz T, et al Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation Am Heart J 2017;183:10–17 291 Ohuchi H, Yasuda K, Miyazaki A, et al Prevalence and predictors of haemostatic complications in 412 Fontan patients: their relation to anticoagulation and haemodynamics Eur J Cardiothorac Surg 2015;47(3):511–519 292 Iyengar AJ, Winlaw DS, Galati JC, et al No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients Eur J Cardiothorac Surg 2016;50(5):980–987 293 Marrone C, Galasso G, Piccolo R, et al Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis Pediatr Cardiol 2011;32(1):32–39 294 Potter BJ, Leong-Sit P, Fernandes SM, et al Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation Int J Cardiol 2013;168(4):3940–3943 295 Monagle P, Cochrane A, McCrindle B, et al Thromboembolic complications after fontan procedures–the role of prophylactic anticoagulation J Thorac Cardiovasc Surg 1998;115(3):493–498 296 McCrindle BW, Manlhiot C, Cochrane A, et al Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure J Am Coll Cardiol 2013;61(3):346–353 297 Monagle P, Chan AKC, Goldenberg NA, et al Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 2012;141(2 suppl):e737S–e801S 298 Schilling C, Dalziel K, Iyengar AJ, d'Udekem Y The cost differential between warfarin versus aspirin treatment after a Fontan procedure Heart Lung Circ 2017;26(8):e44–e47 299 Nguyen N, Anley P, Yu MY, et al Genetic and clinical determinants influencing warfarin dosing in children with heart disease Pediatr Cardiol 2013;34(4):984–990 300 Floyd CN, Goodman T, Becker S, et al Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects Br J Clin Pharmacol 2014;78(2):320–328 301 Hankey GJ, Eikelboom JW Aspirin resistance Lancet 2006;367(9510):606–617 302 Mansour K, Taher AT, Musallam KM, Alam S Aspirin resistance Adv Hematol 2009;2009:937352 303 Giglia TM, Massicotte MP, Tweddell JS, et al Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association Circulation 2013;128(24):2622– 2703 304 Demers C, Mody A, Teo KK, McKelvie RS ACE inhibitors in heart failure: what more do we need to know? Am J Cardiovasc Drugs 2005;5(6):351–359 305 Fu M, Zhou J, Sun A, et al Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction–a meta analysis of 7 prospective clinical studies Int J Cardiol 2012;155(1):33–38 ... 2009;2009:937352 303 Giglia TM, Massicotte MP, Tweddell JS, et al Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association